Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.44 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15842687 | 0.84 | CA12 (0.60) | CYP2A6KDM4ECYP1A2ALDH1A1HPGD | |
| SCHEMBL11094483 | 0.83 | HSD17B3 (0.63) | CYP2A6KDM4ECYP1A2ALDH1A1MAPT | |
| SCHEMBL23332346 | 0.82 | ALDH1A1 (0.61) | CYP2A6KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL15842782 | 0.81 | CYP2A6 (0.67) | CYP2A6KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL6336116 | 0.81 | CYP2A6 (0.51) | CYP2A6KDM4ECYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL7762789 | 0.78 | CYP2A6 (0.63) | CYP2A6KDM4ECYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL12451637 | 0.77 | HSD17B3 (0.68) | KDM4EALDH1A1SMN1; SMN2TDP1NPC1 | |
| SCHEMBL15842498 | 0.76 | KDM4E (0.61) | KDM4ECYP1A2ALDH1A1HPGDNPC1 | |
| SCHEMBL30659713 | 0.76 | NPC1 (0.44) | KDM4EALDH1A1MAPTSMN1; SMN2HPGD | |
| SCHEMBL15842493 | 0.75 | KDM4E (0.73) | CYP2A6KDM4ECYP1A2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050209274-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABOTT LABORATORIES | 2005-09-22 | — | — | US | disclosed |
| EP-0050396-B1 | COUMARIN INTERMEDIATES | BEECHAM GROUP PLC (GB) | 1984-12-27 | — | — | EP | disclosed |
| EP-0010392-B1 | HETEROCYCLIC COUMARIN DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID DERIVATIVES | BEECHAM GROUP PLC (GB) | 1982-12-29 | — | — | EP | disclosed |
| EP-0050396-A1 | Coumarin intermediates | BEECHAM GROUP PLC (GB) | 1982-04-28 | — | — | EP | disclosed |
| US-4263299-A | ANTIHISTAMINES, ANTIALLERGENS | BEECHAM GROUP LIMITED (GB) | 1981-04-21 | — | — | US | disclosed |
| EP-0010392-A1 | Heterocyclic coumarin derivatives, their preparation and pharmaceutical compositions comprising said derivatives | BEECHAM GROUP PLC (GB) | 1980-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209274-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | CYP2A6 2701/4885KDM4E 2305/4885CYP1A2 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.